HanchorBio, Inc. (TWSE: 7827), a clinical-stage biotechnology company headquartered in Taipei, Shanghai, and the San Francisco Bay Area, announced a precision oncology collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a participating subteam in the Taiwan Cancer Moonshot Program (TCMP). The agreement, formalized through a memorandum of understanding signed by HanchorBio's Taiwan subsidiary and Professor Yu's team, integrates TCMP's cancer multi-omics and biomarker discovery capabilities with HanchorBio's proprietary FBDB (Fc-Based Designer Biologics) platform and clinical-stage immuno-oncology pipeline.
The collaboration is platform-level rather than asset-specific. The two parties will combine TCMP's cancer genomics, proteomics, and integrated multi-omics infrastructure — including clinically annotated patient-derived datasets from Taiwanese and East Asian cancer populations — with HanchorBio's FBDB therapeutic engineering and clinical development capabilities.
Yu's team has participated in international proteogenomics initiatives including the US National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium and has published multi-omics studies across lung, gastric, and breast cancers. Under the collaboration, the researchers will investigate biomarkers associated with treatment response and resistance, macrophage-mediated immune regulation and T-cell functional states, with findings potentially incorporated into HanchorBio's clinical development programs.
The FBDB platform, which underpins HanchorBio's clinical pipeline, engineers multi-functional Fc-region fusion proteins intended to activate both innate and adaptive immune pathways. The platform's lead clinical asset, HCB101, is a SIRPα-IgG4 Fc fusion protein targeting the CD47-SIRPα innate immune checkpoint; it holds US FDA Orphan Drug Designation for gastric cancer and is in Phase Ib/IIa combination development. A second asset, HCB301, a tri-specific fusion protein targeting SIRPα/CD47, PD-1/PD-L1, and TGF-β, is in Phase I studies across the US, China, and Taiwan.